Koselugo (Selumetinib)

Koselugo is a kinase inhibitor used for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

Recommended Dosage:  The recommended dosage is 25 mg/m2 orally twice daily (around every 12 hours) until the disease is progressive or unacceptable toxicity. Take koselugo capsules on an empty stomach. Avoid consuming food 2 hours prior to each dose or 1 hour after each dose. Swallow the capsules whole with water. Avoid chewing, dissolving or opening of the capsule. Do not take a missed dose unless it is beyond 6 hours until the next scheduled dose. In case vomiting occurs after capsules administration, do not take an additional dose, but carry on with the next scheduled dose. 

• Assess ejection fraction by echocardiogram prior to starting treatment, every three months during the first year of treatment, every six months thereafter.
• In patients who interrupt therapy with koselugo 25 mg for reduced LVEF, obtain an echocardiogram or a cardiac MRI every 3-6 weeks. 
• Serious ocular toxicities including retinal pigment epithelial detachment (RPED) and retinal vein occlusion (RVO), occurred in an unapproved group of adult patients with multiple tumor types who received selumetinib capsules as a single agent or along with other anti-cancer agents.
• Comprehensive ophthalmic assessments need to be conducted before initiating treatment with selumetinib, at regular intervals during therapy, and for new/worsening visual changes. 
• Severe gastrointestinal toxicities, including ileus, perforation, colitis, and intestinal obstruction, occurred in an unapproved group of adult patients with multiple tumor types who received selumetinib 25 mg capsules as a single agent or along with other anti-cancer agents. 
• Diarrhea occurred in pediatric patients who received selumetinib. Patients should start an anti-diarrheal agent immediately after the first episode of unformed, loose stool and to increase fluid intake during the episodes of diarrhea. 
• Rash occurred in pediatric patients who received selumetinib. Monitor for serious skin rashes. Withhold, reduce dose, or permanently interrupt koselugo 10 mg based on the severity of adverse reaction. 
• Other skin toxicities, including severe palmar-plantar erythrodysesthesia syndrome, appeared in an unapproved group of adult patients with multiple tumor types who received capsules of koselugo as a single agent or along with other anti-cancer agents.
• Serum CPK should be obtained prior to initiating selumetinib 10 mg, periodically during treatment. In case increased CPK occurs, assess patients for rhabdomyolysis or other causes.
• Bleeding may occur in those patients who are co-administered vitamin-K antagonists or anti-platelet antagonists with selumetinib treatment. Patients should be monitored for bleeding.
• Findings from animal studies and mechanism of action suggest that selumetinib can cause fetal harm if administered to a pregnant woman.
•  

What documents are required to import KOSELUGO to India?

KOSELUGO (Selumetinib) capsules can be imported by patients or government hospitals in the name of the patients only.

The following documentation is needed to import the product:

• Valid prescription from a qualified doctor.
• Patients diagnostic reports.
• Patients ID proof (issued by the Government of India).

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• Valid prescription of Doctor.
• Import permit, if applicable.

Is KOSELUGO available in India?

KOSELUGO (selumetinib capsules) is a prescription drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import medicines on the named patient supply (NPS). Urgent Meds is the facilitator providing input on:

• Availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune, etc.).
• Medicine Price.
• Finding genuine and reliable sources from Canada, Europe, the USA, and Australia.
• Ensuring 100% transparency.

KOSELUGO can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

Urgent Meds can facilitate the supply of KOSELUGO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or visit urgentmeds.in for KOSELUGO price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source KOSELUGO (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Koselugo®?

Selumetinib is the Generic Name for the trade name drug Koselugo®.

What is the Manufacturer Name of Koselugo®?

Koselugo® is manufactured by AstraZeneca and MSD, Inc.

Is Koselugo® approved by the FDA?

Yes, Koselugo® is approved by the FDA. Date of approval: April 10, 2020.

What is Koselugo®?

Koselugo® (Selumetinib) is the first and only prescription medicine approved by the FDA to treat children aged 2 years and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely eliminated by surgery.

What is the dosage and form of Koselugo® supplied?

Koselugo® is supplied as Capsules: 10 mg and 25 mg for oral administration.

What are the most common side effects due to Koselugo®?

The most common side effects due to Koselugo® include:

• Dry skin
• Vomiting
• Rash
• Abdominal pain
• Diarrhea
• Nausea
• Fatigue
• Acneiform rash
• Musculoskeletal pain
• Pyrexia
• Stomatitis
• Paronychia
• Headache
• Pruritus

How much does Selumetinib cost in India?

The cost of Selumetinib in India is very reasonable. To procure this neurofibromatosis type-1 medicine authentically, you can call or WhatsApp +1-647-818-4196 or visit urgentmeds.in.

What are the storage conditions of Koselugo®?

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Dispense in the original bottle. Do not eliminate the desiccant. Protect capsules from moisture.